Covid-19 in patients with chronic lymphocytic leukemia: Clinical outcome and Band T-cell immunity during 13 months in consecutive patients
Leukemia and Lymphoma
; 62(SUPPL 1):S136-S137, 2021.
Article
in English
| EMBASE | ID: covidwho-1747052
ABSTRACT
We studied the clinical and immunological outcomes of covid-19 infection in strictly consecutive patients with CLL from a well-defined area during the first 13 months of the pandemic. Sixty patients with a median age of 71 years (range 43-97) were identified. Median CIRS was 8 (4-20), median BMI 25 (19-42) and 65% were men. Patients had indolent CLL (n=38), were previously treated (n=12) or had ongoing therapy (n=10, among which seven received BTKi). Forty-six patients (77%) were hospitalized due to severe covid-19 and among them, 11 (24%) were admitted to the intensive care unit (ICU). Severe covid-19 was equally distributed across subgroups irrespective of age, gender, BMI, CLL status except for comorbidities (CIRS >6, p<0.05). Fourteen patients (23%) died;age ≥75 years was the only significant risk factor (p<0.05, uni- and multivariate analyses). Comparing months 1-6 vs. 7-13 of the pandemic, death rates were reduced from 32 to 18%, ICU admission from 37 to 15% and hospitalizations remained frequent (86 vs. 71%). Seroconversion occurred in 34/41 tested patients (83%) and anti-SARS-CoV-2 antibodies remained detectable at 6 and 12 months of follow-up in 17/22 and 8/11 patients, respectively. In-depth immunological analysis revealed that 13/17 tested patients had neutralizing antibodies (including all 12 patients that were also seropositive in conventional serology in this cohort), and 19/28 (68%) had antibodies in saliva. SARS-CoV- 2-specific T-cells (IFN-gamma ELISpot) were detected in 14/17 patients (82%). We conclude that covid-19 in non-selected CLL patients continued to result in a high admission rate even among young early-stage patients. A robust and durable B and/or T cell immunity was observed in most convalescents.
endogenous compound; gamma interferon; neutralizing antibody; SARS-CoV-2 antibody; aged; body mass; cancer patient; cancer staging; chronic lymphatic leukemia; clinical outcome; cohort analysis; comorbidity; conference abstract; controlled study; convalescence; coronavirus disease 2019; enzyme linked immunospot assay; female; follow up; gender; hospitalization; human; intensive care unit; major clinical study; male; mortality rate; nonhuman; outcome assessment; pandemic; risk factor; saliva; seroconversion; serology; Severe acute respiratory syndrome coronavirus 2; T lymphocyte
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Leukemia and Lymphoma
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS